A phase Ib open-label, escalating repeat-dose trial of bavituximab (chimeric anti-phosphatidylserine monoclonal antibody) in patients with chronic hepatitis C
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2007
At a glance
- Drugs Bavituximab (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Peregrine Pharmaceuticals
- 17 May 2007 Status changed from in progress to completed.
- 14 Feb 2007 Interim results have been reported.
- 12 Jun 2006 New trial record.